Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders

1 . A compound of the structure

wherein

R 1 represents H;

R 2 represents —NH 2 ;

L represents O;

M is CH;

n is 1;

n′ is 0, 1, or 2;

G is methyl or trifluoromethyl;

G′ is methyl or amino;

J is pyridyl or pyrimidyl;

Y is phenyl, pyridyl or pyrimidyl;

or a pharmaceutically acceptable salt thereof.

2 . A compound selected from the group consisting of

6-(2,6-dimethylphenyl)-N 4 -(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)pyrimidine-2,4-diamine)

(6-(6-aminopyridin-3-yl)-N 4 -{4-[(2-methylpyridin-4-yl)oxy]phenyl}pyrimidine-2,4-diamine)

(N 6 -(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)-4,5′-bipyrimidine-2,6-diamine)

(6-phenyl-N 4 -(4-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}phenyl)pyrimidine-2,4-diamine)

and

(6-(6-aminopyridin-3-yl)-N 4 -(4-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}phenyl)pyrimidine-2,4-diamine)

or a pharmaceutically acceptable salt thereof.

3 . A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

4 . The pharmaceutical composition of claim 3 for the treatment or prevention of cancer.

5 . A process for preparing the pharmaceutical composition of claim 3 , comprising combining at least one compound according to claim 1 with at least one pharmaceutically acceptable carrier or excipient and bringing the resulting combination into a form suitable for said pharmaceutical composition.

6 . A method of treatment for a hyperproliferative disorder comprising administering an effective amount of a compound of claim 1 to a subject in need thereof.

7 . The method of claim 6 wherein said hyperproliferative disorder is cancer.

8 . A compound of claim 1 for the treatment or prevention of disorders.

9 . A use of a compound of claim 1 for manufacturing a pharmaceutical composition for the treatment or prevention of a disease.

10 . The use of claim 9 , wherein the disease is cancer.

11 . The use of claim 9 , wherein the use is treatment.

12 . A packaged pharmaceutical composition comprising a container comprising the pharmaceutical composition of claim 3 and instructions for using the pharmaceutical composition to treat a disease or condition in a mammal.

13 . The packaged pharmaceutical composition of claim 12 , wherein the disease or condition is cancer.